Empagliflozin Survival Benefit in Diabetes: Is it Plasma Volume Drop? Empagliflozin Survival Benefit in Diabetes: Is it Plasma Volume Drop?

Changes in hematocrit and hemoglobin accounted for half the effect on CV death seen with empagliflozin in patients with type 2 diabetes in EMPA-REG Outcome, a new analysis confirms.Medscape Medical News

Source: Medscape Medical News Headlines - February 1, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news